Skip to content

US · ACET · BIOTECHNOLOGY

Adicet Bio, Inc. (ACET) intrinsic value and stock valuation

$2.14as of 2026-11-21 · Mkt cap 85.63M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Adicet Bio, Inc. DCF and intrinsic value

InvestorsCraft values ACET with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACET’s statements →

Adicet Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02116 adicetbio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-116.8M
20112025
Free cash flow
-$-96.98M
20112025
Total equity
$159.2M+7.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$25M$9.73M
Operating income-$-122.11M-$-127.61M-$-152.04M-$-72.55M-$-61.43M
Net income-$-116.8M-$-117.12M-$-142.66M-$-69.79M-$-62M
EPSd-$-16.95M-$-21.33M-$-53.03M-$-27.16M-$-32.12M
Operating cash flow-$-95.25M-$-92.38M-$-93.72M-$-44.77M-$-51.05M
Capital expenditure-$-1.74M-$-1.12M-$-4.46M-$-16.78M-$-13.05M
Free cash flow-$-96.98M-$-93.5M-$-98.18M-$-61.55M-$-64.1M
Total assets$192.4M$220.2M$207.3M$330.7M$338.9M
Total debt$14.7M$17.2M$20.9M$21M$20.9M
Net debt-$-24.18M-$-39.26M-$-138.79M-$-236.63M-$-256.6M
Total equity$159.2M$186.6M$170.2M$292.3M$303.1M
Cash and short-term investments$158.5M$176.3M$159.7M$257.7M$277.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$25M$9.73M
Cost of revenue$6.38M$0.00$0.00$0.00$0.00
Gross profit-$-6.38M$0.00$0.00$25M$9.73M
Research and development expenses$99.1M$99.3M$106M$71.3M$48.9M
Selling, general and administrative expenses$23M$28.3M$26.5M$26.3M$22.2M
Other expenses-$-6.38M$0.00$19.5M$0.00$0.00
Operating expenses$115.7M$127.6M$152M$97.5M$71.2M
Cost and expenses$122.1M$127.6M$152M$97.5M$71.2M
Interest income$5.78M$10.7M$9.98M$3.76M$90K
Interest expense$40K$0.00$30K$80K$180K
Depreciation and amortization$6.38M$6.47M$6.1M$5.01M$1.54M
Ebitda-$-110.39M-$-110.65M-$-136.53M-$-64.7M-$-60.41M
Operating income-$-122.11M-$-127.61M-$-152.04M-$-72.55M-$-61.43M
Total other income/expenses, net$5.31M$10.5M$9.38M$2.76M-$-690K
Income before tax-$-116.8M-$-117.12M-$-142.66M-$-69.79M-$-62.12M
Income tax expense$0.00$0.00$0.00$0.00-$-120K
Net income-$-116.8M-$-117.12M-$-142.66M-$-69.79M-$-62M
Weighted average shares outstanding$6.89M$5.49M$2.69M$2.57M$1.93M
Weighted average diluted shares outstanding$6.89M$5.49M$2.69M$2.57M$1.93M
Balance sheet
20252024202320222021
Cash and short-term investments$158.5M$176.3M$159.7M$257.7M$277.5M
Net receivables$340K$0.00$0.00$430K$210K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$160.9M$180.1M$162.3M$261M$282.4M
Property, plant and equipment, net$28.5M$36.8M$44.2M$49M$35M
Goodwill and intangible assets$0.00$0.00$0.00$19.5M$19.5M
Long-term investments$2.87M$0.00$0.00$0.00$0.00
Total non-current assets$31.4M$40.1M$45M$69.7M$56.5M
Total assets$192.4M$220.2M$207.3M$330.7M$338.9M
Accounts payable$4.74M$4.83M$2.62M$4.4M$3.26M
Short-term debt$3.19M$3.13M$3.22M$2.49M$1.57M
Deferred revenue$0.00$0.00$0.00$0.00$4.8M
Total current liabilities$21.5M$19.4M$19.3M$19.7M$16.3M
Long-term debt$11.6M$14.1M$17.7M$18.5M$19.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$11.6M$14.2M$17.8M$18.6M$19.5M
Capital lease obligations$14.7M$17.2M$20.9M$21M$20.9M
Total liabilities$33.2M$33.6M$37.1M$38.4M$35.8M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-614.7M-$-497.89M-$-380.77M-$-238.11M-$-168.32M
Accumulated other comprehensive income (loss)$100K$20K$0.00$0.00$0.00
Total equity$159.2M$186.6M$170.2M$292.3M$303.1M
Total investments$122.5M$119.8M$0.00$0.00$0.00
Total debt$14.7M$17.2M$20.9M$21M$20.9M
Net debt-$-24.18M-$-39.26M-$-138.79M-$-236.63M-$-256.6M
Cash flow statement
20252024202320222021
Net income-$-116.8M-$-117.12M-$-142.66M-$-69.79M-$-62M
Depreciation and amortization$2.29M$6.47M$6.1M$2.58M$1.54M
Stock-based compensation$14.3M$22.2M$20.3M$17.1M$12.5M
Change in working capital$1.47M-$-5.53M$250K$2.74M-$-6.06M
Accounts receivable$0.00$0.00$0.00$180K-$-30K
Inventory$0.00$0.00$0.00$0.00$2.01M
Accounts payable$1.03M$1.11M-$-1.68M$1.71M$1.14M
Net cash provided by operating activities-$-95.25M-$-92.38M-$-93.72M-$-44.77M-$-51.05M
Investments in property, plant and equipment-$-1.74M-$-1.12M-$-4.46M-$-16.78M-$-13.05M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$2.39M-$-119.24M-$-4.46M-$-16.78M-$-2.8M
Common stock issued$75.2M$110.9M$390K$43.4M$238.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$75.3M$111.3M$240K$41.5M$242.7M
Net change in cash-$-17.61M-$-100.31M-$-97.94M-$-20.04M$188.8M
Cash at end of period$41.8M$59.4M$159.7M$257.7M$277.7M
Operating cash flow-$-95.25M-$-92.38M-$-93.72M-$-44.77M-$-51.05M
Capital expenditure-$-1.74M-$-1.12M-$-4.46M-$-16.78M-$-13.05M
Free cash flow-$-96.98M-$-93.5M-$-98.18M-$-61.55M-$-64.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Adicet Bio, Inc.

        Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.

        CEO
        Chen Schor
        Employees
        102
        Beta
        1.59

        Explore

        Frequently asked questions

        What is the intrinsic value of Adicet Bio, Inc. (ACET)?

        InvestorsCraft does not currently publish an intrinsic value for ACET. How the IC value is calculated.

        Is ACET undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACET at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.